As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

As the coro­n­avirus orig­i­nat­ing out of Wuhan spreads to South Ko­rea, Italy and Iran, stok­ing al­ready in­tense fears of a pan­dem­ic, Glax­o­SmithK­line has found an­oth­er pair of trust­ed hands to place its ad­ju­vant sys­tem. Chi­na’s Clover Bio­phar­ma­ceu­ti­cals will add the ad­ju­vant to its pre­clin­i­cal, pro­tein-based vac­cine can­di­date against SARS-CoV-2.

Clover, which is based in the in­land city of Cheng­du, boasts of a plat­form dubbed Trimer-Tag that pro­duces co­va­lent­ly-trimer­ized fu­sion pro­teins. Its can­di­date, COVID-19 S-Trimer, re­sem­bles the vi­ral spike (S)-pro­tein found in the virus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.